CN106660936A - 用于治疗adhd的方法和达斯曲林(dasotraline)组合物 - Google Patents

用于治疗adhd的方法和达斯曲林(dasotraline)组合物 Download PDF

Info

Publication number
CN106660936A
CN106660936A CN201580027069.6A CN201580027069A CN106660936A CN 106660936 A CN106660936 A CN 106660936A CN 201580027069 A CN201580027069 A CN 201580027069A CN 106660936 A CN106660936 A CN 106660936A
Authority
CN
China
Prior art keywords
dastroline
treatment
adhd
dosage form
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580027069.6A
Other languages
English (en)
Chinese (zh)
Inventor
安东尼·龙贝尔
肯尼思·克波兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of CN106660936A publication Critical patent/CN106660936A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580027069.6A 2014-05-13 2015-05-12 用于治疗adhd的方法和达斯曲林(dasotraline)组合物 Pending CN106660936A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992588P 2014-05-13 2014-05-13
US61/992,588 2014-05-13
PCT/US2015/030342 WO2015175514A1 (en) 2014-05-13 2015-05-12 Methods and compositions of dasotraline for treatment of adhd

Publications (1)

Publication Number Publication Date
CN106660936A true CN106660936A (zh) 2017-05-10

Family

ID=54480544

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580027069.6A Pending CN106660936A (zh) 2014-05-13 2015-05-12 用于治疗adhd的方法和达斯曲林(dasotraline)组合物

Country Status (10)

Country Link
US (1) US20170266133A1 (enExample)
EP (1) EP3142999A4 (enExample)
JP (1) JP2017515858A (enExample)
KR (1) KR20170003677A (enExample)
CN (1) CN106660936A (enExample)
AU (1) AU2015259337A1 (enExample)
CA (1) CA2948829A1 (enExample)
IL (1) IL248846A0 (enExample)
MX (1) MX2016014780A (enExample)
WO (1) WO2015175514A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200405867A1 (en) * 2018-01-19 2020-12-31 Sunovion Pharmaceuticals Inc. Oral dosage forms
WO2020092496A1 (en) * 2018-10-31 2020-05-07 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
CN1688538A (zh) * 2002-09-16 2005-10-26 塞普拉科公司 用反式4－(3,4－二氯苯基)－1,2,3,4－四氢－1－萘胺及其甲酰胺治疗cns病症
CN102740842A (zh) * 2009-12-04 2012-10-17 桑诺维恩药品公司 反式降舍曲林的制剂、盐和多晶型物及其应用
WO2012158492A2 (en) * 2011-05-13 2012-11-22 Dainippon Sumitomo Pharma Co., Ltd. Treatment and management of cns disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0314377B8 (pt) * 2002-09-16 2021-05-25 Sepracor Inc composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
CN1688538A (zh) * 2002-09-16 2005-10-26 塞普拉科公司 用反式4－(3,4－二氯苯基)－1,2,3,4－四氢－1－萘胺及其甲酰胺治疗cns病症
CN102740842A (zh) * 2009-12-04 2012-10-17 桑诺维恩药品公司 反式降舍曲林的制剂、盐和多晶型物及其应用
WO2012158492A2 (en) * 2011-05-13 2012-11-22 Dainippon Sumitomo Pharma Co., Ltd. Treatment and management of cns disorders

Also Published As

Publication number Publication date
JP2017515858A (ja) 2017-06-15
KR20170003677A (ko) 2017-01-09
IL248846A0 (en) 2017-01-31
MX2016014780A (es) 2017-07-25
WO2015175514A1 (en) 2015-11-19
EP3142999A4 (en) 2017-12-27
AU2015259337A1 (en) 2016-12-08
EP3142999A1 (en) 2017-03-22
US20170266133A1 (en) 2017-09-21
CA2948829A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
JP6332651B2 (ja) 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
EP3329909B1 (en) Fenfluramine for use in the treatment of dravet syndrome
JP4938905B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
JP2011511071A5 (enExample)
EP3678665A1 (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
CN107072988A (zh) 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合
JP2023181398A (ja) 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置
TW200831097A (en) Treatment of anxiety with eszopiclone
CN106660936A (zh) 用于治疗adhd的方法和达斯曲林(dasotraline)组合物
CN106660937A (zh) 用于治疗adhd的达斯曲林(dasotraline)剂量和方法
WO2014120021A1 (en) A combination medicament comprising phenylephrine and paracetamol
CN104623671A (zh) 含有乙酰胆碱酯酶抑制剂和二甲双胍的复方药用组合物
US20170087104A1 (en) Medicament
JP2023526634A (ja) 高アンモニア血症を治療するためのオルニチンフェニルアセテートの使用
CN116323604A (zh) 5-甲基-1,2,4-噁二唑-3-基化合物的低剂量方案和制剂
US8222278B2 (en) Treatment of attention-deficit/hyperactivity disorder
Mentazac Almuriva (UK); Altigmin (Turkey); Alzerta (Spain); Alzest (UK); Alzigmine (Israel).• Balaxon (Greece); Begusin (Poland).

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170510